COMMUNIQUÉS West-GlobeNewswire

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

07/11/2017 - 17:15

HASBROUCK HEIGHTS, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the [...]

Canada Diagnostic Centres Contracts with eRAD

07/11/2017 - 16:42

GREENVILLE, S.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- eRAD announced today that Canada Diagnostic Centres (CDC), a 17-site imaging provider in Alberta, Canada, will implement an array of eRAD software solutions, including [...]

VBL Therapeutics to Report Third Quarter 2017 Results on November 14

07/11/2017 - 16:29

TEL AVIV, Israel, Nov. 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]

CORRECTING and REPLACING – Elite Pharmaceuticals, Inc.

07/11/2017 - 16:27

NORTHVALE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP), please note in the headline the conference call date should be "November 10" rather than [...]

ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA

07/11/2017 - 15:13

Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 7 November 2017 Orphazyme A/S ("Orphazyme" or the "Company"), a Danish biotech company with a late stage orphan [...]

STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress

07/11/2017 - 15:00

SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX ) (“Cytori” or “the Company”) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell [...]

BioStem Technologies, Inc. Launches SEO Optimized Website and Facility Expansion to Include Schedule III-V DEA Product Storage

07/11/2017 - 15:00

Pompano Beach, FL, Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that, Qualified Pharma Ingredients, Inc. (QPI), an Active Pharmaceutical Ingredients [...]

Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders

07/11/2017 - 15:00

OXNARD, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology announced today that it has entered into a product development agreement with [...]

NSS Labs Announces 2017 Next Generation Intrusion Prevention System Group Test Results

07/11/2017 - 15:00

AUSTIN, Texas, Nov. 07, 2017 (GLOBE NEWSWIRE) -- NSS Labs, Inc., a global leader and trusted source for independent fact-based cybersecurity guidance, today announced the results of its Next Generation Intrusion [...]

Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017

07/11/2017 - 15:00

LAWRENCEVILLE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, [...]

Women In Bio Announces that Alpna Seth Joins Bio-Techne’s Board of Directors

07/11/2017 - 15:00

Boardroom Ready Program’s Tenth Board Appointment of its Women graduates NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Women In Bio (WIB), an organization of professionals committed to promoting careers, leadership, and [...]

Genmab to Present at the Jefferies 2017 London Healthcare Conference

07/11/2017 - 14:56

Media Release Copenhagen, Denmark; November 7, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the company’s CEO, Jan van de Winkel, Ph.D., will present an update at the Jefferies 2017 London Healthcare [...]

UPDATE -- Tabula Rasa HealthCare Announces Third Quarter 2017 Results and Revised Financial Outlook

07/11/2017 - 14:52

MOORESTOWN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC ), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital [...]

Zealand Pharma will attend the Jefferies Healthcare Conference in London and the Bryan Garnier & Co Healthcare Conference in Paris, both in November

07/11/2017 - 14:48

Press release - No. 10 / 2017 Zealand Pharma will attend the Jefferies Healthcare Conference in London and the Bryan Garnier & Co Healthcare Conference in Paris, both in November Copenhagen, November 7, 2017 - Mats [...]

Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics

07/11/2017 - 14:43

NOVATO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ) ("Ultragenyx" or the "Company"), a biopharmaceutical company focused on the development of novel products for rare and [...]

Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051

07/11/2017 - 14:30

CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

07/11/2017 - 14:30

NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO ) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]

Collegium Receives FDA Approval for sNDA for Xtampza® ER

07/11/2017 - 14:30

CANTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) announced today that the U.S. Food and Drug Administration (FDA) approved its Supplemental New Drug Application (sNDA) to [...]

Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma

07/11/2017 - 14:30

MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB ), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that the ongoing median overall [...]